AIM ImmunoTech Inc.
AIMAMEXHealthcareBiotechnology
Previous close
$0.2584
+$0.0053 · +2.09%
AIM company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
17
Overpriced
Momentum
17
Strong Down
Sentiment
50
Mixed
Risk resilience
30
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Thomas K. Equels
- Listed since
- Nov 2, 1995
- Employees
- 19
Market position
Day range
Current $0.2584
52-week range
Current $0.2584
- Open
- $0.2631
- Previous close
- $0.2531
- Volume
- 863.99K
- 0.04× average
- Average volume
- 19.56M
- Average daily volume
- Market cap
- 879.48K USD
- Beta
- 1.19
- Market reference 1
- 50-day average
- $0.2898
- -10.84% below average
- 200-day average
- $0.7724
- -66.55% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 5.79M USD
- P/E (TTM)
- -0.07×
- P/B (TTM)
- 0.57×
- P/S (TTM)
- 9.26×
- EV / EBITDA
- -0.45×
- Earnings yield
- -763.13%
- Free cash flow yield
- -619.72%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -125.26%
- Operating margin
- -11637.89%
- Net margin
- -15021.05%
- Return on equity
- 142.68%
- Return on assets
- -241.40%
- Return on invested capital
- -313.55%
Financial health
- Debt / equity
- 0.51×
- Current ratio
- 0.53×
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
3 ratingsLimited analyst sample: 3 ratings. Interpret the distribution with caution.
AIM news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 10, 2026 | 1,031:1,000 | — | — |
Stock split | Jun 12, 2025 | 1:100 | — | — |
Stock split | Jun 11, 2019 | 1:44 | — | — |
Stock split | Aug 29, 2016 | 1:12 | — | — |
Effective Feb 10, 2026
1,031:1,000
Effective Jun 12, 2025
1:100
Effective Jun 11, 2019
1:44
Effective Aug 29, 2016
1:12
AIM peers
Continue in GoAI
Research AIMresearch.disclaimer